Skip to main content

Solventum Corp

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

SOLV$90.43+0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 1A. Risk Factors

Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or our industry, as well as risks that affect businesses in general. In addition to the factors set forth under the caption "Cautionary Note Concerning Forward-Looking Statements" set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the risk factor set forth below, which updates, and should be read in conjunction with, the risk factors disclosed in such Annual Report on Form 10-K. Other than the risk factor set forth below, we believe there have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.

Discussion of these factors is incorporated by reference into and considered an integral part of Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Risks related to Solventum's review of strategic alternatives for its health information system business

We are evaluating strategic alternatives for our health information systems business. The review may not result in the

identification or implementation of a strategic alternative, and any alternative that is pursued may not be completed within

any given timeframe or at all. We may be unable to successfully execute any strategic alternative or realize any or all

strategic, operational, or financial benefits. The review process may also create uncertainty to our customers, employees

and other constituencies or counterparties and divert management attention from ongoing operations. We may incur costs

and expenses in connection with the review process, whether or not a transaction is successful. In addition, we may

determine to abandon the review, pursue a different structure, or take no action. Any of these factors could have a material

adverse effect on our business, financial condition, results of operations, or cash flows.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.